期刊
BRITISH JOURNAL OF CANCER
卷 102, 期 4, 页码 645-650出版社
SPRINGERNATURE
DOI: 10.1038/sj.bjc.6605548
关键词
bone mineral density (BMD); breast cancer; risk factors; fracture risk; guidelines; bone loss
类别
资金
- Amgen
- AstraZeneca
- Eli Lilly
- GlaxoSmithKline
- Novartis
- Novo Nordisk
- Organon
- Pfizer
- Procter Gamble
- Roche
- Sanofi-Aventis
- Solvay
- Wyeth
BACKGROUND: Breast cancer (BC) therapies can have negative effects on bone. Current guidelines recommend antiresorptive therapy based on bone mineral density (BMD), and emerging guidelines include both clinical risk factors and BMD to assess the overall fracture risk. A retrospective, case-controlled study based on current and emerging guidelines was conducted in women with newly diagnosed BC to identify those who were at increased fracture risk based on current and emerging guidelines. METHODS: Baseline characteristics, fracture risk factors, and lumbar-spine (LS) and total-hip BMD in women with BC (88 premenopausal and 402 postmenopausal) were assessed to determine who would receive bisphosphonate therapy based on current and emerging guidelines. RESULTS: Among patients with estrogen-receptor-positive (ER+) BC, 18.8% of premenopausal and 36.9% of postmenopausal women were osteopenic at LS. In the postmenopausal cohort, osteoporosis was more prevalent in patients with ER+ vs ER- BC. Current guidelines identified 8.9% of patients as eligible for antiresorptive therapy, clinical risk factors alone identified 6.5%, and BMD plus clinical risk factors identified 28.6%. CONCLUSIONS: In addition to fracture risk factors present at BC diagnosis, cancer therapies leading to BMD loss further increase fracture risk. Evaluating both BMD and clinical risk factors may allow more effective identification of BC patients with elevated fracture risk. British Journal of Cancer (2010) 102, 645-650. doi:10.1038/sj.bjc.6605548 www.bjcancer.com Published online 19 January 2010 (C) 2010 Cancer Research UK
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据